Gabelli Funds LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,800 shares of the biopharmaceutical company’s stock after buying an additional 800 shares during the period. Gabelli Funds LLC’s holdings in Regeneron Pharmaceuticals were worth $2,635,000 at the end of the most recent quarter.
Several other hedge funds have also bought and sold shares of the stock. San Francisco Sentry Investment Group CA acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth $233,000. Schaper Benz & Wise Investment Counsel Inc. WI increased its stake in Regeneron Pharmaceuticals by 59.3% in the third quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 5,392 shares of the biopharmaceutical company’s stock worth $2,168,000 after buying an additional 2,007 shares during the period. Princeton Capital Management Inc. increased its stake in Regeneron Pharmaceuticals by 14.6% in the third quarter. Princeton Capital Management Inc. now owns 2,235 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 284 shares during the period. Biondo Investment Advisors LLC increased its stake in Regeneron Pharmaceuticals by 402.0% in the third quarter. Biondo Investment Advisors LLC now owns 11,470 shares of the biopharmaceutical company’s stock worth $4,611,000 after buying an additional 9,185 shares during the period. Finally, Sei Investments Co. increased its stake in Regeneron Pharmaceuticals by 3.6% in the third quarter. Sei Investments Co. now owns 197,217 shares of the biopharmaceutical company’s stock worth $79,285,000 after buying an additional 6,801 shares during the period. Hedge funds and other institutional investors own 67.25% of the company’s stock.
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) traded down 2.04% during midday trading on Friday, hitting $459.91. The stock had a trading volume of 1,658,740 shares. The firm has a market cap of $48.55 billion, a price-to-earnings ratio of 55.67 and a beta of 1.53. The firm has a 50-day moving average price of $450.98 and a 200-day moving average price of $392.16. Regeneron Pharmaceuticals, Inc. has a 1-year low of $325.35 and a 1-year high of $489.00. Regeneron Pharmaceuticals also saw some unusual options trading on Wednesday. Stock investors purchased 1,049 call options on the stock. This is an increase of 368% compared to the typical daily volume of 224 call options.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.99% and a net margin of 19.34%. The firm’s revenue was up 9.8% compared to the same quarter last year. During the same period last year, the business posted $2.57 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post $12.66 EPS for the current fiscal year.
A number of analysts recently weighed in on REGN shares. Sanford C. Bernstein restated an “outperform” rating and issued a $410.00 price target (down from $420.00) on shares of Regeneron Pharmaceuticals in a research note on Thursday, February 16th. Goldman Sachs Group, Inc. (The) cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Thursday, February 16th. Piper Jaffray Companies set a $446.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, March 8th. Vetr raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $475.44 price objective for the company in a report on Wednesday, March 15th. Finally, Oppenheimer Holdings, Inc. began coverage on Regeneron Pharmaceuticals in a report on Thursday, March 16th. They set a “hold” rating for the company. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $434.17.
In related news, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, May 12th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the director now directly owns 3,000 shares of the company’s stock, valued at $1,350,000. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, June 9th. The stock was sold at an average price of $482.55, for a total value of $482,550.00. Following the sale, the director now directly owns 14,000 shares in the company, valued at $6,755,700. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 25,674 shares of company stock worth $11,852,498. 10.40% of the stock is currently owned by company insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.